Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells

International Journal of Cancer

Volumn 120, Issue 7, 2007, Pages 1491-1498

  Tomihara, Kei ^a   Kato, Kazunori ^a   Masuta, Yukari ^a   Nakamura, Kiminori ^a   Tanaka, Toshihiro ^a   Hiratsuka, Hiroyoshi ^a   Hamada, Hirofumi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Adenoviral vector; CD40 ligand; Dendritic cells; IFN ; NK cells; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; HUMAN CELL; MOUTH CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNOLOGY; VIRUS INFECTION;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; CD40 LIGAND; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MOUTH NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 33847647564     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22518     Document Type: Article

References (38)

1. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
2. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
3. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-41.
4. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-51.
5. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004;104:3267-75.
6. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
7. Palucka K, Banchereau J. Linking innate and adaptive immunity. Nat Med 1999;5:868-70.
8. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-72.
9. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000;96:91-9.
10. Kikuchi T, Miyazawa N, Moore MA, Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000;60:6391-5.
11. Miyazaki A, Sato N, Takahashi S, Sasaki A, Kohama G, Yamaguchi A, Yagihashi A, Kikuchi K. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Jpn J Cancer Res 1997;88:191-7.
12. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002;13:613-26.
13. Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N, Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 1998;9:2503-15.
14. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T, Sugano S, Saito 1. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific ere recombinase. Nucleic Acids Res 1995;23:3816-21.
15. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997;3:808-11.
16. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, Hamada H. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004;10:162-71.
17. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989;143:1123-8.
18. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183-91.
19. Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright" + and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol 1989;142:2949-54.
20. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188:2375-80.
21. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70.
22. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
23. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y, Kaneda K. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996;157:3967-73.
24. Eischen CM, Schilling JD, Lynch DH, Krammer PH, Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996;156:2693-9.
25. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
26. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270:7025-8.
27. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996;271:5965-7.
28. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayahsi S, Hashimoto H, Kipps TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-55.
29. Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI. Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J Immunol 1989;143:4282-6.
30. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
31. Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F. Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005;113:605-10.
32. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
33. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-97.
34. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-53.
35. Sheikh MS, Huang Y, Fernandez-Salas EA, El-Deirv WS, Friess H, Amundson S, Yin J, Meltzer SJ, Holbrook NJ, Fornace AJ, Jr. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999;18:4153-9.
36. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000;74:281-6.
37. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D, Wiley SR. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999;163:920-6.
38. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU, Mackall CL. Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004;64:8349-56.